earnings
confidence high
sentiment negative
materiality 0.60
Perspective Therapeutics Q2 net loss $21.5M, EPS -$0.29; cash $192M; VMT-α-NET Cohort 3 opened
Perspective Therapeutics, Inc.
2025-Q2 EPS
reported -$0.54
vs consensus -$0.31
▼ miss
(-75.4%)
- Net loss of $21.5M ($0.29 per share) vs $11.7M ($0.18) in Q2 2024; operating expenses rose 65%.
- Cash, cash equivalents & short-term investments $192M as of June 30, sufficient into late 2026.
- R&D expenses $16.6M (+79% YoY) driven by clinical site activities and drug product costs.
- FDA alignment obtained to open Cohort 3 (6.0 mCi) for [212Pb]VMT-α-NET; two patients dosed as of July 31.
- VMT01 melanoma program: combination with nivolumab cohort opened; five monotherapy patients treated.